

Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial

NCT06668389

Status	RECRUITING
Phase	Phase 4
Sponsor	The University of Hong Kong
Enrollment	106 participants

Key Eligibility Criteria

Inclusion (3)

- rTOF
- Aged 18 years or above
- Voluntarily agrees to participate in the clinical trial and provide written informed consent

Exclusion (14)

- Heart failure with reduced ejection fraction (HFrEF) with LVEF \leq 40%
 - Planned cardiac and/or non-cardiac surgery in 3 months
 - Chronic kidney disease stages 4 to 5
 - Unable to perform cardiopulmonary test
 - Recent use of SGLT2 inhibitors within 6 months
- ... and 9 more (see full listing online)

Locations (1 total)

Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong